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Abstract: Recently, a gammaherpesvirus was described in domestic cats (FcaGHV1). The goal of
the present study was to investigate the presence of FcaGHV1 in Swiss domestic cats and analyze
potential risk factors. Blood samples from 881 cats presented to veterinarians in all Swiss cantons
and from 91 stray cats and neoplastic tissue samples from 17 cats with lymphoma were evaluated.
FcaGHV1 was detected by real-time PCR targeting the glycoprotein B gene, followed by sequencing.
Blood samples were also tested for feline hemoplasmas, feline leukemia virus (FeLV) and feline
immunodeficiency virus (FIV). The molecular prevalence of FcaGHV1 was 6.0% (95% confidence
interval (CI), 4.5–7.8%) in cats presented to veterinarians and 5.5% (95% CI, 1.8–12.4%) in stray cats.
FcaGHV1 PCR-positive cats originated from 19/26 Swiss cantons. Factors significantly associated
with FcaGHV1 detection included male sex, age >3 years, nonpedigree status and co-infection with
FIV and hemoplasmas. Moreover, FeLV viremia tended to be associated with FcaGHV1 detection.
High FcaGHV1 blood loads were found more frequently in FeLV-viremic cats and less frequently in
hemoplasma-infected cats than in uninfected cats. Clinical information was unavailable for most
of the 881 cats, but leukemia, carcinoma and cardiomyopathy were reported in FcaGHV1-positive
cats. None of the tissue samples from the 17 cats with lymphoma tested positive for FcaGHV1.
Sequence analyses revealed homogeneity among the Swiss isolates and >99.7% identity to published
FcaGHV1 sequences. In conclusion, FcaGHV1 is present in Switzerland with a similar prevalence
in cats presented to veterinarians and in stray cats. The pathogenic potential of FcaGHV1 needs
further evaluation.
Keywords: cat; gammaherpesvirus; Switzerland; qPCR; virus load; hemoplasma; FeLV; FIV;
retrovirus; veterinary sciences
1. Introduction
Gammaherpesviruses (GHVs) are double-stranded DNA viruses. They belong to the Herpesviridae
family, which includes three subfamilies: Alpha-, Beta- and Gammaherpesvirinae [1,2]. GHVs can
infect humans, establishing a lifelong persistent infection mostly without evident clinical signs [3].
Host immunity is supposed to eliminate the infection, but frequently the virus undergoes latency
with potential reactivation. GHV reactivation is suspected during co-infections or when cell-mediated
immunity is compromised. In the latter cases, the virus can cause severe diseases that can be potentially
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fatal [4,5]. Two human GHVs are known to promote tumorigenesis in humans: Epstein–Barr virus and
Kaposi’s sarcoma-associated herpesvirus [6–9]. Epstein–Barr virus is commonly identified in adult
human beings worldwide. The virus is normally innocuous; however, in a few cases, it can cause
lymphomas, carcinomas or other types of cancer. Loss of T-cell immunity and genetic predisposition
are thought to be critical risk factors for the oncogenic potential of the Epstein–Barr virus [4,5].
GHVs are known to infect different mammalian species, and they are reported worldwide [10–18].
Novel GHVs were identified among Primates, Artiodactyla, Perissodactyla, Carnivora, Scandentia,
and Eulipotyphla using PCR with panherpesvirus DNA polymerase gene primers or genus-specific
glycoprotein B (gB) gene primers [19]. In 2014, the first gammaherpesvirus (named Felis catus
gammaherpesvirus 1, FcaGHV1 [20]) was identified in domestic cats, followed by the identification
of novel GHVs in other felids (bobcats, pumas, ocelots, leopard cats) in the USA and Japan [20–22].
Since that first identification, different epidemiological studies have shown that FcaGHV1 infection
is widely endemic in domestic cats. Most epidemiological studies are based on the detection of the
genus-specific glycoprotein B gene by PCR [19]. The reported worldwide prevalence of FcaGHV1
ranges from 1.3% to 23.6% in domestic cats [20,22–27]. Direct comparison between prevalence studies
is difficult. Differences in prevalence may reflect variations in the studied cat population, the study
inclusion criteria (such as feral free-roaming cats captured for neutering programs, feral cats housed in
animal shelters or privately-owned cats) and the health status of the sampled cats. In addition, it is
important to remember that the identification of FcaGHV1 DNA material does not provide information
on the infection status of the animal and cannot differentiate between virus-infected cells, virion
particles or free DNA [28]. More recently, a serological assay was developed to assess the exposure rate
to FcaGHV1 within a cat population [29]. The seroprevalence of FcaGHV1 was found to be higher than
the molecular prevalence detected by PCR [29], with approximately 50% of the FcaGHV1-seropositive
cats being PCR-positive [20,27,29].
The pathogenic potential of FcaGHV1 in cats remains unclear. It has been shown that FcaGHV1
is more frequently identified in sick cats than in healthy cats [30]. In addition, age, sex, and
concomitant co-infections have been identified as risk factors for FcaGHV1, with some regional
variations. A significant association between FcaGHV1 and feline leukemia virus (FeLV) antigenemia
was identified only in one study in Singapore [27], but this association was not confirmed recently [31].
The prevalence of FcaGHV1 is, however, increased in cats co-infected with feline immunodeficiency
virus (FIV) and FeLV [27,31]. In addition, an association between FIV alone and FcaGHV1 has
been reported in independent studies [23,25,26]. FIV is a widespread feline retrovirus sharing
similarity with human immunodeficiency virus (HIV) that may cause an acquired immunodeficiency
syndrome (AIDS)-like syndrome in infected cats. Additionally, FIV and HIV are two viral infections
that can increase the risk of high-grade B cell lymphomas [30,32–35]. Interestingly, 15–20% of
HIV-associated lymphomas are correlated with human gammaherpesviruses (Epstein–Barr virus and
Kaposi’s sarcoma-associated herpesvirus) [32,36]. Thus, similar to human GHVs, FcaGHV1 in cats
may be a cofactor for malignant transformation in lentivirus-infected individuals.
In the present study, we (i) assessed for the first time the molecular prevalence of FcaGHV1 in
cats in Switzerland; (ii) evaluated potential risk factors associated with FcaGHV1 detection, such as
geographic origin (canton), the age, sex and breed of the cat and co-infections with FeLV, FIV, and
the three feline hemoplasma species; (iii) evaluated the presence of FcaGHV1 in neoplastic tissues of
cats with lymphoma; and (iiii) sequenced a fragment (316 nucleotides) of the glycoprotein B gene of
FcaGHV1 to further elucidate the phylogenetic relationship with other FcaGHV1 isolates and assess
possible genetic variation in Switzerland.
Our study assessed the molecular prevalence of FcaGHV1 and risk factors associated with
this infection in Switzerland for the first time. Remarkably, FcaGHV1 prevalence was similar in
cats presented to veterinarians and in stray cats. In accordance with previous studies, factors
significantly associated with FcaGHV1 detection included male sex, age >3 years, nonpedigree status
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and co-infections with FIV and hemoplasmas. Swiss FcaGHV1 isolates revealed homogeneity and
>99.7% identity to previously published FcaGHV1 sequences.
2. Materials and Methods
2.1. Sample Collection
The study included two sets of feline blood samples. First, the study included 881
EDTA-anticoagulated blood samples collected from domestic cats presented to veterinarians in
Switzerland between 2013 and 2016 [37]. The study was designed to include at least 20 blood samples
from each of the 26 Swiss cantons, and samples were selected only by the postal code associated with
the cat owners. The samples had been described and analyzed for FeLV provirus and antigen, and the
results were previously presented elsewhere [37]. The samples were collected as part of a diagnostic
workup by veterinarians for routine purposes, and only the remaining sample volume was used for
this study. Therefore, no ethical approval was necessary to comply with Swiss regulations [38]. One cat
per owner was included as far as known. In some cases, demographic data of the cats obtained at the
time of sampling were available: breed (n = 639), sex (n = 641) and age (n = 636).
Second, 91 EDTA-anticoagulated blood samples collected from stray cats in the canton of Jura
(Switzerland) were included. These samples were collected by veterinarians during a capture and
neutering program for diagnostic purposes (health check). Demographic data of the cats were available
in some cases: sex (n = 85) and age (n = 11). The samples had been collected in August and October
2014. No breed information was available for the cats. More results on these samples will be presented
elsewhere [39].
In addition, lymphoma tissue samples from six field cats and 11 specific-pathogen-free (SPF)
cats experimentally infected with FeLV and/or FIV were analyzed. Tissue samples from the six field
cats were taken for routine diagnostic purposes only; therefore, no ethical approval was necessary to
comply with Swiss regulations [38]. These samples included six lymph node, two liver, one spleen and
two ileum samples. All of these latter cats were diagnosed with T-cell lymphomas, including one case
of large granular lymphocyte lymphoma. All 11 SPF cats with lymphoma had been experimentally
infected with FeLV in unrelated studies; two had additionally been infected with FIV [40–48]. At the
start of the unrelated studies and before entering the SPF facility, all SPF cats had been tested for selected
feline infectious agents, including alpha herpesvirus (feline herpesvirus 1) but not FcaGHV1 [49].
Tissue samples from the FeLV-infected SPF cats with high grade T-cell lymphoma (one with secondary
blood infiltration) and from the FeLV-FIV-infected cats with mostly high grade T-cell lymphomas and
one with high grade B-cell lymphoma had been collected during necropsy in unrelated studies [40–48].
Seven samples were from tumor tissues (including lymph node, thymus, and ovary), and four were
bone marrow samples. All samples were snap-frozen in liquid nitrogen and stored at −80 ◦C until
further use.
2.2. Nucleic Acid Extraction
Total nucleic acid (TNA) samples were extracted from 100 µL of EDTA-anticoagulated blood using
a MagNaPure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics, Rotkreuz, Switzerland) following
the manufacturer’s instructions as reported previously [37]. All TNA samples were stored at−80 ◦C until
further use. During all extractions, negative controls consisting of 100 µL of phosphate-buffered saline
(PBS) were concurrently prepared with each batch of 15 samples to monitor for cross-contamination.
For the analyzed tissues, samples were homogenized as previously described [50], and genomic DNA
was extracted using a QIAamp DNA Tissue Kit (Qiagen, Hombrechtikon, Switzerland). Negative
extraction controls consisting of phosphate-buffered saline were included with each batch.
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2.3. Quantitative TaqMan Real-Time PCR Assays
To test for the presence of sufficient amounts of amplifiable TNA and the absence of significant
PCR inhibitors, all TNA samples were analyzed for feline albumin (fALB) using real-time qPCR as
previously described [51]. Samples with insufficient amplification (Ct value > 30) were re-extracted;
detailed information was previously reported [37]. All samples with sufficient amounts of amplifiable
TNA were tested for the presence of FcaGHV1 using a quantitative real-time qPCR assay targeting the
viral glycoprotein B gene, as previously reported [20]. Each reaction was carried out in a final volume of
25 µL containing (final concentrations) 12.5 µL of 2× qPCR Mastermix (Eurogentec, Seraing, Belgium),
0.25 µL (0.5 U) of uracil-N-glycosylase (UNG, Eurogentec, Seraing, Belgium), 1.125 µL (900 nM) of
each primer, 0.625 µL (250 nM) of probe, and 5 µl of template DNA. A synthetic double-stranded
DNA (GeneArt String DNA, ThermoFisher Scientific Inc., Waltham, MA, USA) portion (600 bp) of the
FcaGHV1 glycoprotein B gene containing the assay target sequence was used for assay validation and
the quantification of viral loads. To determine the efficiency and linear range of amplification of the
PCR assay, a 10-fold serial dilution of synthetic DNA template in 30 µg/mL carrier salmon sperm DNA
(ThermoFisher Scientific, Reinach, Switzerland) spanning nine orders of magnitude (1 × 100–1 × 108
copies per reaction) was examined.
All samples had also been tested for FeLV proviral DNA, as previously reported [37]. Briefly,
for the detection of FeLV provirus, a real-time qPCR assay specific for exogenous FeLV LTR U3 was
applied [45].
Moreover, 106 of the 881 samples were additionally tested for the three feline hemoplasmas:
Mycoplasma haemofelis (Mhf), ‘Candidatus Mycoplasma haemominutum’ (CMhm) and ‘Candidatus
Mycoplasma turicensis’ (CMt). The 106 samples included 53 FcaGHV1 PCR-positive samples and 53
FcaGHV1 PCR-negative samples. The 53 FcaGHV1 PCR-negative samples were chosen from all the
FcaGHV1 PCR-negative samples to match—as well as possible—the FcaGHV1 PCR-positive samples
concerning the following parameters: the origin (Swiss canton of provenience), age, sex and pedigree
status of the cat. There was no significant difference between FcaGHV1 PCR-negative and positive cats
regarding sex (pChi2 = 0.9171), percentage of pedigree cats (pChi2 = 1.000) and age (pChi2 = 0.0794)
(Supplementary Figure S1). The three feline hemoplasmas (Mhf, CMhm, and CMt) were detected,
and blood loads were quantified using specific real-time qPCR assays targeting the 16S rRNA gene as
previously described [52,53]. The real-time qPCR detection limit for the hemoplasmas (all three assays)
is one copy per PCR, which corresponds to 200 copies/mL of blood [52,53].
In addition, lymphoma tissue samples from six field cats and 11 specific-pathogen-free (SPF) cats
experimentally infected with FeLV and/or FIV were tested for FeLV proviral DNA [37] and FIV proviral
DNA [54]. For FIV, a real-time RT-PCR was performed according to a modified version of the method
used by Wang et al. [55], which used 900 nM of both the upstream (FIV_gag_upstr: 5′- ATG GGG AAY
GGA CAG GGG CGA GA-3′) and downstream (FIV_gag_downstr: 5′- TCT GGT ATR TCA CCA GGT
TCT CGT CCT GTA-3′) primers and 250 nM fluorogenic probe (FIV_gag_F2ABCEmIM 5′-FAM-TGG
CCA TWA ARA (iQ500)GAT GYA GTA ATG TTG CTG TAG G-BHQ1-3′), 0.625 µL (40 U/µL) RNasinR
Plus (Promega, Madison, WI, USA), 12.5 µL 2× RT qPCR Reaction Mix, 0.5 µL SuperscriptTM III
RT/PlatinumR Taq mixture and 0.05 µL ROX (all from the SuperscriptTM III PlatinumTM One-Step
qRT-PCR kit, ThermoFisher Scientific, Carlsbad, CA, USA) in a final volume of 25 µL. The reaction mix
underwent reverse transcription at 50 ◦C for 15 min, denaturation and activation for 2 min at 95 ◦C
and 45 cycles of 95 ◦C for 15 s and 60 ◦C for 30 s.
All qPCR assays were performed using an ABI 7500 Fast Sequence Detection System (Applied
Biosystems, ThermoFisher Scientific, Reinach, Switzerland). Positive and negative controls were
included in each PCR run. The primers and probes used in the present study are shown in Table 1.
Viruses 2019, 11, 721 5 of 20
Table 1. Primers and probes employed in this study.
Primer Set Name Target Gene Sequence (5′ - 3′) Amplicon Size (bp4) Reference
Felis catus gammaherpesvirus1 1
Forward primer
Glycoprotein B
ACA TCT TCA CTG GAC AAC TGG
113 [20]Reverse primer GTG CAT TTG ATG TCC TGA CTG
Probe FAM - TGA ACA GCT GAG TCT CTA CAA GTC TCC A -BHQ1
Felis catus gammaherpesvirus1 2
Forward primer Glycoprotein B ACC TGC ACC AGA GCA TGA GA 360 [27]Reverse primer TGT CCA GTA CGT TAG CCA ATC TTT
Feline albumin 3
Forward primer
Albumin
GAT GGC TGA TTG CTG TGA TT
150 [51]Reverse primer CCC AGG AAC CTC TGT TCA TT
Probe FAM - ATC CCG GCT TCG GTC AGC - TAMRA
Feline leukemia virus
Forward primer
FeLV LTR U3
AAC AGC AGA AGT TTC AAG GCC
131 [45]Reverse primer TTA TAG CAG AAA GCG CGC G
Probe FAM - CCA GCA GTC TCC AGG CTC CCC A - TAMRA
Feline immunodeficiency virus
Forward primer
FIV gag
ATG GGG AAY GGA CAG GGG CGA GA
164 [54,55]Reverse primer TCT GGT ATR TCA CCA GGT TCT CGT CCT GTA
Probe FAM-TGG CCA TWA ARA (iQ500)GAT GYA GTA ATG TTGCTG TAG G-BHQ1
Mycoplasma haemofelis
Forward primer
16S rRNA
GAA AGT CTG ATG GAG CAA TAC CAT
118 [53]Reverse primer CTG GCA CAT AGT TWG CTG TCA CTT A
Probe VIC - AGT ACT ATC ATA ATT ATC CCT CG - BHQ1
‘Candidatus Mycoplasma
haemominutum’
Forward primer
16S rRNA
GAA AGT CTG ATG GAG CAA TAC CAT
141 [53]Reverse primer CTG GCA CAT AGT TWG CTG TCA CTT A
Probe FAM - AAG GCT TAA TCA TTT CCT - BHQ1
‘Candidatus Mycoplasma turicensis’
Forward primer
16S rRNA
GAA GGC CAG ACA GGT CGT AAA G
85 [52]Reverse primer CTG GCA CAT AGT TWG CTG TCA CTT A
Probe FAM - AAA TTT GAT GGT ACC CTC TGA - BHQ1
1 Primers and probe used for the real-time PCR assay (113 bp amplicon size), 2 Primers used for sequencing (360 bp amplicon size), 3 The assay was used for quality control to test for the
integrity of genomic DNA and the absence of PCR inhibitors; 4 bp, base pairs.
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2.4. Detection of FeLV Antigen and FIV Antibodies
Among the 881 blood samples, FeLV provirus-positive samples were additionally tested for
FeLV p27 antigen [37] using a sandwich enzyme-linked immunosorbent assay [56]; antigenemia is
a marker of FeLV infection and, in most but not all cats, a parameter of viremia [57]. Cats were
considered antigenemic when the antigen level in their samples was 20% of the positive control value
in the p27 antigen ELISA [37]. Of the 106 matched samples (see above), 104 were also tested for FIV.
For two of the 106 matched samples, no material remained for FIV testing; these samples included
one FcaGHV1-positive and one FCaGHV1-negative sample. Antibodies against FIV were detected by
Western blot analysis as described previously [58,59]. Samples with antibodies against the p15 and p24
bands were considered positive.
2.5. Sequencing and Phylogenetic Analysis of the FcaGHV1 Swiss Isolates
Three FcaGHV1-positive samples were selected and subjected to sequencing. For this purpose, a
360 bp fragment of the glycoprotein B gene was amplified by PCR (Table 1) as previously described [27].
The reaction was performed in a T-personal 48 thermal cycler (Biometra GmbH, Göttingen, Germany)
in a total volume of 50 µL containing 10 µL of 5× Phusion HF buffer (Finnzymes, Espoo, Finland),
500 nM each primer, 200 nM each deoxynucleoside triphosphate (dNTP) (Sigma-Aldrich, Buchs,
Switzerland), 1 U Phusion DNA Polymerase (Finnzymes, Espoo, Finland) and 5 µL of template DNA.
The thermal cycling program comprised a step at 98 ◦C for 3 min; 35 cycles at 98 ◦C for 10 s, 57 ◦C for
30 s, and 72 ◦C for 30 s; and a final step at 72 ◦C for 10 min.
PCR products were analyzed on a 1.5% agarose gel prestained with a commercial gel stain
(GelRed™ Nucleic Acid Stain, Biotium, Inc., Fremont, CA, USA) and were then visualized by UV
transillumination. The AccuBand™ 100 bp DNA ladder II (SMOBIO®, Hsinchu City, Taiwan) was
used as the standard to initially determine the molecular mass of PCR products. Amplicons with
the expected size were excised from the gel, purified using a QIAquick Gel Extraction Kit (Qiagen
AGHombrechtikon, Switzerland), and cloned using a TOPO TA Cloning Kit with the PCR™II-TOPO®
vector and One Shot TOP10 chemically competent Escherichia coli, based on the manufacturer’s
instructions (Invitrogen, Basel, Switzerland). The recombinants obtained were selected and grown in
large quantities for plasmid extraction using a QIAprep Spin Miniprep Kit (Qiagen AG, Hombrechtikon,
Switzerland) and were subjected to automated DNA sequencing with vector-specific M13 forward
and reverse primers at a commercial laboratory (Microsynth, Balgach, Switzerland) under standard
conditions. Sequences were edited and assembled using Geneious® (v 11.1.5, Biomatters Limited,
Auckland, New Zealand). After trimming the vector and primer sequences, the resulting 316 bp
consensus sequence of the glycoprotein B gene was aligned and compared for similarity with those
available in the GenBank database using Basic Local Alignment Search Tool (BLAST) analysis [60].
Phylogenetic analysis was conducted using MEGA-X (Molecular Evolutionary Genetics Analysis,
Kumar) [61]. Sequences were aligned to additional reference sequences retrieved from GenBank
using the ClustalW algorithm [62]. The phylogenetic tree was inferred via the maximum likelihood
method using a distance matrix corrected for nucleotide substitutions based on the Kimura 2-parameter
model [63]. The dataset was resampled 1000 times to generate bootstrap values [64]. The partial
FcaGHV1 glycoprotein B nucleotide sequences obtained in this study have been deposited in the
GenBank database under accession numbers MK572745–MK572747.
2.6. Statistical Analysis
Statistical analysis was performed using GraphPad Prism (version 8.1, GraphPad Software, San
Diego, CA, USA). The FcaGHV1 molecular prevalence rates were calculated with 95% confidence
intervals (CI). Frequencies were compared using Fisher’s exact test for small numbers (pF) and using
the chi-square test (pChi2). To compare continuous variables (FcaGHV1 blood loads) between two
groups, the nonparametric Mann–Whitney U-test was used (pMW). The following variables were tested
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for statistical association with FcaGHV1 detection in the first set of 881 cats presented to veterinarians:
origin (canton of Switzerland), breed (pedigree and nonpedigree cats), age (≤3 years vs. >3 years), sex
and reproductive status (castrated male, intact male, spayed female, and intact female), FeLV provirus
and antigen positivity, and FIV and hemoplasma infection status. Considering the small number
of cats with sufficient data in the second set of samples (n = 91 stray cats from the canton of Jura),
no statistical analyses were performed concerning the age and sex of the cats. Correlations between
the FcaGHV1 blood loads and ages of the cats and the FcaGHV1 molecular prevalence and human
population density was calculated using nonparametric Spearman rank correlation (pS; r = correlation
coefficient). P-values < 0.05 were considered significant.
3. Results
3.1. Efficiency, Sensitivity and Linear Range of Amplification of the FcaGHV1 Real-Time qPCR Assay
The efficiency and linear range of amplification of the FcaGHV1 real-time qPCR assay were
determined using 10-fold serial dilutions of the standard. Amplification of FcaGHV1 showed linearity
over the whole range of dilution (Figure 1). The highest dilution still yielded a positive signal containing
one copy per reaction. In the endpoint dilution experiment, the dilution with 1 copy yielded 8 positive
reactions of 10. For the next lower dilution, none of the 8 reactions was positive. Thus, the lower
limit of detection was 1 copy of template per 5 µL reaction, corresponding to 200 copies per milliliter
of blood.
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by subtracting the baseline value.
3.2. Sample Characteristics
In the first set of 881 samples from cats presented to veterinarians throughout all cantons of
Switzerland (Table 2), the samples originated from 160 pedigree and 479 nonpedigree cats, and no
information was available for 242 samples (Table 3). The sex and reproductive status data revealed
308 castrated male and 207 spayed female cats and 56 male and 70 female intact animals (the sex and
reproductive status of 240 cats were unknown). The cats’ ages varied from 2 months to 21.5 years; the
median age was 6.6 years (the age of 244 cats was unknown).
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Table 2. Origin of the 881 samples included in the Swiss FcaGHV1 molecular prevalence study. The
number of samples and the molecular FcaGHV1 prevalence rates are listed.
Canton of Switzerland FcaGHV1-Negative FcaGHV1-Positive Total % FcaGHV1 Prevalence(95% CI 1)
Aargau (AG) 46 5 51 9.8 (3.3–21.4)
Appenzell I.Rh. (AI) 21 3 24 12.5 (2.7–32.4)
Appenzell A.Rh. (AR) 19 1 20 5.0 (0.1–24.9)
Bern (BE) 43 4 47 8.5 (2.4–20.4)
Basel-Landschaft (BL) 22 2 24 8.3 (1.0–27.0)
Basel-Stadt (BS) 19 2 21 9.5 (1.2–30.4)
Fribourg (FR) 42 3 45 6.7 (1.4–18.3)
Geneva (GE) 33 1 34 2.9 (0.1–15.3)
Glarus (GL) 20 0 20 0.0 (0–16.8)
Graubünden (GR) 37 1 38 2.6 (0.1-13.8)
Jura (JU) 20 4 24 16.7 (4.7–37.4)
Lucerne (LU) 32 3 35 8.6 (1.8–23.1)
Neuchâtel (NE) 45 0 45 0.0 (0–7.9)
Nidwalden (NW) 36 4 40 10 (2.8–23.7)
Obwalden (OW) 29 2 31 6.5 (0.8–21.4)
St. Gallen (SG) 28 0 28 0.0 (0–12.3)
Schaffhausen (SH) 18 2 20 10.0 (1.2–31.7)
Solothurn (SO) 26 0 26 0.0 (0–13.2)
Schwyz (SZ) 43 4 47 8.5 (2.4–20.4)
Thurgau (TG) 22 0 22 0.0 (0–15.4)
Ticino (TI) 44 6 50 12.0 (4.5–24.3)
Uri (UR) 19 1 20 5.0 (0.1–24.9)
Vaud (VD) 53 0 53 0.0 (0–6.7)
Valais (VS) 47 0 47 0.0 (0–7.5)
Zug (ZG) 22 2 24 8.3 (1.0–27.0)
Zurich (ZH) 42 3 45 6.7 (1.4–18.3)
Total 828 53 881 6.0 (4.5–7.8)
1 CI, confidence interval. The three highest FcaGHV1 molecular prevalences are marked in bold.
Table 3. Sample characteristics of the 881 cats in the Swiss prevalence study and the FcaGHV1 molecular
prevalence rates.
Variable Category FcaGHV1-Negative(n = 828)
FcaGHV1-Positive
(n = 53) Total (n = 881)
% FcaGHV1
Prevalence
(95% CI 1)
Pedigree Yes 158 2 160 1.3 (0.2–4.4)
No 440 39 479 8.1 (6.0–10.9)
Unknown 230 12 242 5.0 (2.9–8.5)
Sex M 53 3 56 5.4 (1.5–14.9)
MC 278 30 308 9.7 (6.9–13.6)
F 66 4 70 5.7 (2.2–13.8)
FS 201 6 207 2.9 (1.3–6.2)
Unknown 230 10 240 4.2 (2.3–7.5)
Age (years) ≤ 1 98 2 100 2.0 (0.4–7.0)
>1 ≤ 2 50 0 50 0.0 (0.0–7.1)
>2 ≤ 3 45 1 46 2.2 (0.1–11.3)
> 3 ≤5 70 6 76 7.9 (3.7–16.2)
> 5 ≤ 10 151 13 164 7.9 (4.7–13.1)
> 10 ≤ 15 133 14 147 9.5 (5.8–15.4)
> 15 47 6 53 11.3 (5.3–22.6)
Unknown 234 11 245 4.5 (2.5–7.9)
1 CI, confidence interval; M, male; MC, male castrated; F, female; FS, female spayed.
For the second set of samples collected from 91 stray cats in the canton of Jura, limited information
was available: 48 cats were intact females and 37 cats were intact males; the information was unavailable
for six cats. The ages of the 11 cats with available information were <1 year for five cats, 1–3 years for
four cats and >3 years for four cats.
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3.3. Sample Prevalence of FcaGHV1 in Swiss Domestic Cats
Of the 881 cats from all cantons of Switzerland, 53 tested as FcaGHV1-positive (6.0%; 95% CI,
4.5–7.8%). FcaGHV1 PCR-positive samples originated from 19 of the 26 Swiss cantons (Table 2 and
Figure 2). Overall, although the molecular prevalence ranged from 0% to 16.7% in each canton, there was
no significant difference in FcaGHV1 molecular prevalence among the different cantons of Switzerland
(pChi2 = 0.1576; Table 2; Figure 2). From Figure 2, however, it is evident that fewer FcaGHV1-positive
cats were found in the Alps than in the other two major Swiss natural environments—the Swiss
Plateau and the Jura region. The highest molecular prevalence of FcaGHV1 was found in the canton of
Jura (16.7%; 95% CI, 4.7–37.4%), followed by the canton of Appenzell Innerrhoden (12.5%; 95% CI,
2.7–32.4%) and the canton of Ticino (12.0%; 95% CI, 4.5–24.3%; Table 2).
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Figure 2. Origin of the 881 cats presented at veterinary facilities in all 26 cantons of Switzerland and of
the 91 stray cats from Jura. FcaGHV1 PCR-positive samples from cats presented to veterinarians are
represented by red circles, and those from stray cats in Jura by red squares. FcaGHV1 PCR-negative
samples from cats presented to veterinarians are shown as green circles, and those of stray cats as
green squares. The circle diameters are proportional to the number of positive or negative cases in
the considered village/town. The squares and circles are not directly proportional; the squares are
somewhat reduced in size for better visualization. The Swiss cantons are shaded in different colors.
Major lakes and rivers are depicted in blue.
e aimed to assess hether the density of the cat population in the different S iss cantons plays
a role in FcaG V1 olecular prevalence. Since no data are available on the cat density in each S iss
canton, e used the hu an density as an approximation [65]. The hu an population density in the
three cantons sho ing the highest FcaG V1 olecular prevalence (Jura, Appenzell Innerrhoden and
Ticino) ranges from 87 to 129 people/km2 [65]. FcaG V1 as not detected in any of the tested cats
from seven cantons: Glarus, Solothurn, Neuchâtel, Sant Gallen, Thurgau, Vaud and Valais. The human
population density in these cantons ranges from 59 to 341 people/km2 [65]. There was no statistical
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association between the human population density and the FcaGHV1 molecular prevalence in cats (n
= 26; pS = 0.4649; r = 0.01818; 95% CI, −0.3822–0.4128).
Among the stray cats originating from the canton of Jura, five of 91 were FcaGHV1-positive (5.5%;
95% CI, 1.8–12.4%). There was no significant difference in the molecular prevalence of FcaGHV1
between stray cats (5.5%; 95% CI, 1.8–12.4%) and cats presented to veterinarians in the canton of Jura
(4 of 24; 16.7%; 95% CI, 4.7–37.4%; pF = 0.4664).
3.4. Association of FcaGHV1 Detection with Nonpedigree Status, Male Sex and Age >3 Years
The association of FcaGHV1 detection with breed, sex and age was assessed in the 881 cats
presented to veterinarians. Pedigree cats were significantly less frequently FcaGHV1-positive (2/160;
1.3%; 95% CI, 0.2–4.4%) than nonpedigree cats (39/479; 8.1%; 95% CI, 6.0–10.9%; pF = 0.0012; odds
ratio (OR) 7.0; 95% CI, 1.9–29.8; Table 3). The two pedigree cats that were FcaGHV1-positive were
one Sphinx and one Maine Coon cat. There was a significant difference in sex and reproductive status
between FcaGHV1-positive and negative cats (pChi2 = 0.0223; Table 3). Male cats (intact and castrated)
were more frequently FcaGHV1-infected (33/364; 9.1%; 95% CI, 6.5–12.5%) than female cats (intact and
spayed; 10/277; 3.6%; 95% CI, 2.0–6.5%; pF = 0.0064; OR 2.7; 95% CI, 1.3–5.4). There was a significant
difference in the age distribution between FcaGHV1-positive and negative cats (pChi2 = 0.0422; Table 3).
When the molecular prevalence in the different age groups was examined, it became evident and
was confirmed by statistical analysis that cats older than 3 years were significantly more frequently
FcaGHV1-positive (39/440; 8.9%; 95% CI, 6.6–11.9%) than cats less than 3 years of age (3/196; 1.5%; 95%
CI, 0.4–4.4%); pF = 0.0002; OR 6.3; 95% CI, 2.0–19.5).
3.5. Association of FcaGHV1 with Other Infectious Agents
In the first set of feline samples (n = 881), 47 samples were FeLV provirus-positive (5.3%; 95%
CI, 3.9–7.0%), of which four were also FcaGHV1-positive (Table 4); in addition, 18 samples were
viremic (2.0%; 95% CI, 1.2–3.2%), of which three were also FcaGHV1-positive (Table 4). FeLV-viremic
(p27 antigen-positive) cats tended to be more frequently FcaGHV1-positive (3 of 18; 16.7%) than
FeLV-aviremic cats (50 of 863; 5.8%; pF = 0.0884; OR 3.3; 95% CI, 0.97–11.1; Table 4). There was no
statistical difference between the molecular prevalence of FcaGHV1 in FeLV provirus-positive cats and
that in FeLV provirus-negative cats (pF = 0.5202; Table 4).
Table 4. FcaGHV1 and feline leukemia virus (FeLV) infection in the 881 cats presented to
Swiss veterinarians.
Variable Category FcaGHV1-Negative FcaGHV1-Positive % FcaGHV1Prevalence (95% CI 1)
Odds Ratio (95%
CI) P-Value
2
FeLV Aviremic 813 50 5.8 (4.3–7.6) Ref.
Viremic 15 3 16.7 (3.6–41.4) 3.3 (0.97–11.1) 0.0884
FeLV
provirus Negative 785 49 5.2 (3.8–6.9) Ref.
Positive 43 4 7.5 (2.1–18.2) 1.5 (0.6–5.5) 0.5202
1 CI, confidence interval; 2 Fisher’s exact test.
In addition, 104 of the 881 samples were tested for FIV, including 52 FcaGHV1-positive samples
and 52 of the FcaGHV1-negative matched samples. Among the 104 tested samples, 23 were positive
for FIV by Western blot analysis (22.1%; 95% CI, 14.6–31.3%). FIV-positive cats were more frequently
FcaGHV1-positive (20 of 23; 87.0%) than FIV-negative cats (32 of 81; 39.5%; pF <0.0001; OR 10.2;
95% CI, 2.8–37.2; Table 5). Overall, 106 of the 881 samples were also tested for feline hemoplasma
infections, including the 53 FcaGHV1-positive and 53 matched FcaGHV1-negative samples. Among
these 106 samples, 27 were positive for at least one hemoplasma species (25.5%; 95% CI, 17.5–34.9%).
Cats positive for any feline hemoplasma species were significantly more frequently FcaGHV1-positive
(19 of 28; 67.9%) than hemoplasma-negative cats (34 of 78; 43.6%; pF = 0.0463; OR 3.1; 95% CI, 1.2–8.0;
Table 5). The same pattern held for CMhm-positive cats, since all hemoplasma-positive cats were also
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positive for CMhm: cats positive for CMhm were significantly more frequently FCaGHV1-positive
than CMhm-negative cats (pF = 0.0463; OR 3.1; 95% CI, 1.2–8.0). None of the cats had a single infection
with Mhf or CMt. Of the 19 cats positive for both hemoplasma and FcaGHV1, four were concurrently
PCR-positive for more than one hemoplasma species, including three cats co-infected with CMt and
CMhm and one cat co-infected with CMhm and Mhf. All the FcaGHV1-negative cats were PCR-positive
only for CMhm. None of the FcaGHV1-negative cats were PCR-positive for more than one feline
hemoplasma. No blood samples of the cats presented to veterinarians tested positive for all three
hemoplasma species.
Table 5. Feline immunodeficiency virus (FIV) infection and feline hemoplasma infection in selected
samples from the 881 cats presented to Swiss veterinarians.
Variable Category FcaGHV1-Negative FcaGHV1-Positive % FcaGHV1Prevalence (95% CI 1)
Odds Ratio (95%
CI) P-Value
2
FIV 3 Negative 49 32 39.5 (28.8–51.0) Ref.
Positive 3 20 87.0 (66.4–97.2) 10.2 (2.8–37.2) <0.0001
Hemoplasma 4 Negative 44 34 43.6 (32.4–55.3) Ref.
Positive 9 19 5 67.9 (47.6–84.1) 2.7 (1.1–6.8) 0.0463
1 CI, confidence interval; 2 Fisher’s exact test; 3 FIV infection was investigated in 104 samples: 52 FcaGHV1-positive
cats and 52 matched FcaGHV1-negative cats (see M&M). 4 Hemoplasma infections were investigated in 106 samples:
53 FcaGHV1-positive cats and 53 matched FcaGHV1-negative cats (see M&M). Hemoplasma-negative/-positive =
negative for all hemoplasmas tested/positive for any of the three hemoplasmas tested. 5 This group included 3 cats
co-infected with CMt and CMhm and one cat co-infected with Mhf and CMhm.
In the second set of feline samples (n = 91 stray cats from the canton of Jura), 7 samples were FeLV
provirus-positive (7.7%; 95% CI, 3.1–15.2%), but none of the FeLV provirus-positive cats were also
FcaGHV1 PCR-positive. No serum samples were available to test for FIV. Seventeen of the 91 whole
blood samples were positive for at least one hemoplasma species (18.7%; 95% CI, 11.3-28.2%). Notably,
all five FcaGHV1-positive cats were also hemoplasma-positive (Table 6), and hemoplasma PCR-positive
cats were more frequently FcaGHV1-positive (5 of 17; 29.4%) than FcaGHV1-negative (0 of 74; 0%; pF
= 0.0001; OR 65.6; 95% CI 3.4–1261). Among the 91 tested samples, seven tested PCR-positive for Mhf
(7.7%; 95% CI, 3.1-15.2%), 12 for CMhm (13.1%; 95% CI, 7.0-22%), and two for CMt (2.2%; CI, 0.3-7.7%).
Among those samples, two were concurrently PCR-positive for all three hemoplasma species (Mhf,
CMhm, and CMt). One of these two samples was also FcaGHV1 PCR-positive.
Table 6. Feline hemoplasma infections in the 91 stray cats from the canton of Jura (Switzerland).
Variable Category FcaGHV1-Negative FcaGHV1-Positive % FcaGHV1Prevalence (95% CI 1)
Odds Ratio (95%
CI) P-Value
2
Hemoplasma 3 Negative 74 0 0.0 (0.0–4.9) Ref.
Positive 12 5 29.4 (10.3–56.0) 65.6 (3.4–1261) 0.0001
1 CI, confidence interval; 2 Fisher’s exact test; 3 Hemoplasma-negative/-positive = negative for all three hemoplasma
species tested/positive for any of the three hemoplasmas tested.
3.6. FcaGHV1 Blood Loads
The FcaGHV1 blood loads in this study ranged from 200 (the detection limit) to 3.9 × 105
copies/mL of blood. There was no significant difference in the blood loads between the samples from
the 53 FcaGHV1-positive cats presented to veterinarians and the five FcaGHV1-positive stray cats
(pMW = 0.4956). When the FcaGHV1 blood loads in the 881 cats presented to veterinarians were
grouped into “low” (<800 copies/mL; n = 31) and “high” loads (>1000 copies/mL; n = 22), FeLV
provirus-positive cats significantly more frequently exhibited high FcaGHV1 loads (4/4; 100%; 95% CI,
40–100%) than FeLV provirus-negative cats (18/49; 37%; 95% CI, 23–52%; pF = 0.0250; OR 15.3; 95% CI,
0.8–301). There was also a tendency for FeLV-viremic cats to more frequently exhibit high FcaGHV1
loads (3/3; 100%; 95% CI, 29–100%) than FeLV-aviremic cats (19/50; 38%; 95% CI, 25–53%; pF = 0.0657;
OR 11.3; 95% CI 0.6–231). In contrast, hemoplasma-positive cats significantly less frequently exhibited
high FcaGHV1 loads (4/19; 21%; 95% CI, 6.1–46%) than hemoplasma-negative cats (18/34; 52%; 95% CI,
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35–70%; pF = 0.0408; OR 0.23; 95% CI, 0.07–0.86). There was no statistical difference in the FcaGHV1
loads between FIV-positive and FIV-negative cats (pMW = 0.1295). In addition, there was no statistical
association between the FcaGHV1 blood loads and the age of the positive cats (n = 42; pS = 0.5495;
r = 0.095; 95% CI, -0.224–0.396).
3.7. Clinical Presentation of Some FcaGHV1-Positive Cats
Clinical information (presenting clinical signs, pretreatment, and diagnosis) was available for
selected FcaGHV1 PCR-positive cats presented to the Clinic for Small Animal Internal Medicine (n = 7).
This information was compared to that of age-, sex- and breed-matched FcaGHV1 PCR-negative cats
presented at the same clinic in this study (n = 12).
Four of the seven FcaGHV1-positive cats had a history of pretreatment with glucocorticoids for
one or several days, and only two were current on their vaccinations against feline parvovirus, feline
herpesvirus-1 and feline calicivirus. Five of the seven FcaGHV1-positive cats had cardiorespiratory
signs, with final diagnoses of hypertrophic cardiomyopathy (HCM) (n = 3) and/or bronchopneumonia
(n = 2), pyothorax (n = 1), and feline asthma (n = 1). In the latter cat, squamous cell carcinoma of the
cheek with metastasis to the regional lymph node was confirmed after surgical excision. In one of
the two cats without cardiorespiratory signs (cat 2223639), immune-mediated hemolytic anemia was
diagnosed, which, after 4 weeks of glucocorticoid treatment, was determined to be acute leukemia.
Further characterization of the acute leukemia was not possible. The other positive cat (cat 2236869)
was 20 years old with chronic kidney disease (CKD) and secondary chronic vomiting and weight loss.
In comparison, only 2 of the 12 FcaGHV1-negative cats with clinical information had a history of
pretreatment with glucocorticoids (one day), and all except one were current on their vaccinations.
None of those cats showed cardiorespiratory signs; 7/12 presented because of gastrointestinal signs
(vomiting, diarrhea and/or anorexia). The final diagnoses in these cats were pancreatitis (n = 2),
food-responsive inflammatory bowel disease (n = 1), cholangitis (n = 1), GI bleeding (n = 1) and
lymphoma (n = 2). Three of the other 5 cats showed neurological signs (permethrin intoxication, n = 1;
otitis media, n = 1; meningioma, n = 1). The final diagnoses in 2 of the 5 cats were diabetes mellitus
and fibrosarcoma (showing a large mass on the lateral abdomen). There was no difference in outdoor
access between the FcaGHV1 PCR-positive and -negative cats. The clinical diagnoses of the seven
selected FcaGHV1-positive cats are shown in Table 7.
Table 7. Clinical information for selected FcaGHV1-positive cats.
Cat ID Breed Age (Years) Sex Clinical Signs
2228157 EU-Longhair 7 MC Hypertrophic cardiomyopathy, CKD
2156335 Maine Coon 13 FS Bronchopneumonia
2235402 Sphinx 5 MC Hypertrophic cardiomyopathy, pneumonia, pyothorax
2236869 EU-Shorthair 20 MC CKD
2223639 EU-Shorthair 7 MC Immune mediated hemolytic anemia, acute leukemia
2186282 EU-Shorthair 7 MC Hypertrophic cardiomyopathy, chronic diarrhea
2200223 Maine Coon mixed breed 12 MC Feline asthma, carcinoma (SCC)
ID, identity; EU, European cat; MC, male castrated; FS, female spayed; CKD, chronic kidney disease; SCC, squamous
cell carcinoma.
3.8. Sequence Analysis
The results of the FcaGHV1 qPCR assay were confirmed by the sequencing of a 316 bp fragment
of the glycoprotein B gene of FcaGHV1 from three random samples. Two samples (BE26 and
AR3) showed identical sequences, and the third sample (LZ11) differed from the others by one
nucleotide (a synonymous nucleotide polymorphism). The sequences of the former samples were
100% identical to the FcaGHV1 sequence from Australian infected cats (GenBank KJ561572 [27]) and
sequences from Germany, Austria, the USA and Japan (KP862648, KP862649, KF840717, and LC198234,
respectively [20,23,25]) and 99.7% identical to that from a Singaporean cat (KJ561573 [27]). Phylogenetic
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analysis showed that the Swiss FcaGHV1 sequences (MK572745-MK572747) clustered together with
FcaGHV1 sequences from domestic cats, bobcats and ocelots, in the genus Percavirus (Figure 3).
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is shown. The percentage of trees i which the associated taxa clustered together is shown next
to the branches. The gammaherpesvirus genera (Percavirus, Macavirus, Lymphocryptovirus an
Rhadinovirus) are shown in color. Initial tree(s) for the heuristic search were obtained automatically
by applying the Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated
using the maximum composite likelihood (MCL) approach and then selecting the topology ith
the highest log likelihood value. The tree is drawn to scale, with branch lengths measured in the
number of substitutions per site. Bootstrap support from 1000 replicates is shown for each branch
node (values below 60 are not displayed). The analysis included 39 nucleotide sequences. There was
a total of 335 positions in the final dataset. Evolutionary analyses were conducted in MEGA X [61].
The betaherpesvirus human cytomegalovirus (HHV5) was the outgroup.
3.9. Absence of FcaGHV1 in Lymphomas
No e of the analyzed tumor or bone marrow samples from the 17 cats with lymphoma were
positive for FcaGHV1. This sample set included samples from nine SPF cats experimentally infected
with FeLV, two cats coinfected with FeLV and FIV, and six samples collected from clinical cases in field
cats. The latter six samples collected from the clinical cases tested PCR-negative for FeLV and FIV.
The lymphoma cases included both B- and T-cell lymphoma.
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4. Discussion
This study is the first to investigate the presence of FcaGHV1 in Switzerland. A molecular
prevalence of 6.0% (95% CI, 4.5–7.8%) was found for FcaGHV1 in domestic cats presented to
veterinarians throughout Switzerland. A similar molecular prevalence was noted in stray cats
in Switzerland (5.5%; 95% CI, 1.8–12.4%). FcaGHV1 PCR-positive cats originated from 19 of the 26
Swiss cantons, and no significant difference in the prevalence of FcaGHV1 infection was observed
among the different cantons. However, there was an obvious geographic clustering of FcaGHV1
detection in the Swiss Plateau and Jura region of Switzerland compared to the Alps. This pattern
could indicate that the climate or certain vectors could play a role in FcaGHV1 transmission. We also
investigated whether there was an association with population density; as no data are available on
the cat density in each Swiss canton, we used the human density as an approximation [65], assuming
that a higher number of people indicates a higher number of cats. There was no association between
the density of the human population and the molecular prevalence of FcaGHV1 infection in domestic
cats. Thus, either our assumption was wrong and many of the cats in more highly populated regions
do not have outdoor access providing contact to other cats, or cat density is not associated with the
FcaGHV1 detection.
In contrast, we did find an association between FcaGHV1 detection and the sex of the cats.
Male cats were more likely to be infected with FcaGHV1 than female cats. A higher FcaGHV1 infection
risk for male cats was reported in prevalence studies from the USA, Europe, Brazil, Tsushima Island
(Japan) and Australia [20,22–24,26,27]. Male cats were also more likely to be seropositive than female
cats, using the newly developed serological assay for FcaGHV1 [29]. It has been speculated that male
cats may be at higher risk of viral exposure due to their strong territorial behavior, which often leads
to aggressive interactions among cats [20,23,27,28]. Biological factors such as hormonal differences
between male and female cats could also potentially influence host immunity or viral replication [20,66].
Cross-sectional epidemiological data using structural equation models further showed that host
phenotypic traits such as aggressive male phenotypes are real FcaGHV1 disease risk factors and not
simply correlated events [67]. This important epidemiological finding suggests horizontal transmission
by direct animal contact (e.g., during territorial aggression or through contaminated objects) as one
possible route of FcaGHV1 infection. This hypothesis is supported by the recent identification of
FcaGHV1 in oronasal swabs and tissues collected from infected cats [68]. Oronasal secretions, therefore,
might play an important role in the transmission of FcaGHV1 among cats.
We found that cats greater than three years of age were at increased risk of being FcaGHV1
PCR-positive. The age of the cats also seems to play a role in the FcaGHV1 prevalence in other studies,
where adult cats were more frequently infected than young cats [20,23,25–27,29]. The observation that
adult cats are more frequently infected than young animals supports the assumption that FcaGHV1
infection cannot be cleared by the cat’s immune system, leading to lifelong infection and increasing
infection rates with increasing age of the cats. Interestingly, it was recently reported that cats can be
infected with FcaGHV1 from two months of age [68]. None of the younger cats (< 2 months of age)
were FcaGHV1 PCR-positive [68].
FcaGHV1 infections have been associated with several other infectious agents [23–27]. In the
present study, FIV was identified as a risk factor for FcaGHV1 detection. FIV was previously recognized
as a risk factor, and higher FcaGHV1 blood loads were found in FIV-infected cats than in FIV-negative
cats in Europe, Australia [23,27], Brazil [26] and Japan [25]. The association between FcaGHV1
and FIV may be because FIV may lead to immunosuppression in infected cats, and this, in turn,
may facilitate FcaGHV1 replication or escape from latency [27]. FeLV viremia also tended to be
associated with FcaGHV1 detection. We found a tendency for FeLV viremic cats to be more frequently
FcaGHV1-infected than FeLV aviremic cats. Progressive FeLV infection with persistent FeLV viremia
was previously reported to induce loss of cell (neutrophil and lymphocyte) function and changes in
cytokine patterns, leading to the clear dysfunction of the immune system and a decrease in tumor
surveillance mechanisms, causing an increased risk of tumor development in infected cats [69].
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These alterations of the immune system in viremic FeLV-infected cats may explain the tendency toward
the increased frequency of FcaGHV1 detection in FeLV-viremic cats compared to that in FeLV-aviremic
cats. Interestingly, we also found that FeLV-viremic and FeLV provirus-positive cats more frequently
exhibited high FcaGHV1 blood loads than uninfected cats. FeLV was not consistently identified as a
risk factor for FcaGHV1 alone [27,31], but cats co-infected with FIV and FeLV were identified as having
an increased risk [31]. It is known that FeLV–FIV co-infections have a more severe influence on a cat’s
immune system than FIV or FeLV alone [43,69,70]. The present study showed that both single FIV and
single FeLV infection may have an effect on FcaGHV1 detection. It cannot be determined whether
this effect is actually due to an immunosuppressive effect of feline retroviruses, since immunological
parameters such as CD4+ counts have not been investigated in FcaGHV1-infected cats, or whether the
association could also be based on similar transmission routes. However, in stray cats, no association
was found between FeLV infection and FcaGHV1 detection; this lack of association could imply that not
a similar method of transmission but rather actual immunosuppression, which is more detrimental and
probably more quickly fatal in stray cats than in privately-owned cats presented to veterinarians, is the
basis of this association. Alternatively, the small number of stray cats may have limited the statistical
analysis; however, this possibility seems less likely since the percentage of FeLV provirus-positive stray
cats (7.7%) was rather high and was higher than that of cats presented to veterinarians (5.3%).
We also identified hemoplasma infections as risk factors for FcaGHV1 in cats presented to
veterinarians as well as in stray cats. Hemoplasmas were also previously recognized as risk
factors for FcaGHV1 [24,27]. Again, the real meaning of the association between hemoplasma
and FcaGHV1 infections has not yet been identified; however, these two infections may indeed share
similar transmission routes, such as aggressive contact between cats in an outdoor environment or
vector-borne transmission. In addition, we found two cats concurrently infected with all three feline
hemoplasma species: Mhf, CMhm and CMt. Both cats were stray cats, and one of the two cats was
also FcaGHV1 PCR-positive. Concurrent infections with all three feline hemoplasmas have rarely been
reported previously.
The pathogenic potential of FcaGHV1 in domestic cats is not completely understood. It was
shown that FcaGHV1 PCR-positive cats are 2.8 times more likely to be ill than healthy [27]. However,
this association (FcaGHV1 and illness) could not be shown in other studies [23]. In the present study,
clinical information was available only for a limited number of cats; none of the FcaGHV1-positive
cats had lymphoma, but two of the matched FcaGHV1-negative cats did. This finding was consistent
with the negative results of all our tested lymphoma tissue samples. Interestingly, the majority of the
FcaGHV1-positive cats with available clinical data showed cardiorespiratory signs, with a confirmed
diagnosis of hypertrophic cardiomyopathy in three of these cats. Although one of these cats was a Maine
Coon cat, a breed in which the incidence of hypertrophic cardiomyopathy is known to be increased,
none of the three FcaGHV1-negative Maine Coon cats exhibited hypertrophic cardiomyopathy.
An association between FcaGHV1 and cardiomyopathy has not been reported previously. However,
Epstein–Barr virus, another GHV, was detected in humans with cardiomyopathy, suggesting a possible
association between the virus and the otherwise unexplained cardiomyopathy [71]. FcaGHV1 DNA
was detected in multiple tissues from infected cats, including heart tissue [27]. More studies are needed
to further evaluate the possible association of FcaGHV1 and cardiomyopathy in a larger number of cats.
Whether glucocorticoid or immunosuppressive treatment and vaccination status have any influence
on FcaGHV1 infection and pathogenesis can only be speculated, as our number of cases was small.
In humans, two GHVs (Epstein–Barr virus and Kaposi’s sarcoma-associated herpesvirus) are
associated with the development of cancer [72]. FcaGHV1 was isolated in T and B lymphocytes
of cats but not in feline myeloid cells [73]. This pattern supports the hypothesis that FcaGHV1 is
lymphotropic, as reported for the other GHVs. In a recent study analyzing 122 feline lymphoma
cases (including histological and/or cytological preparations), no association was found between
FcaGHV1 and the development of lymphoma in cats [74]. The absence of an association, however,
does not rule out a pathogenic role of the virus [74]. To further evaluate the role of FcaGHV1 in
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lymphomagenesis, transcriptome analysis and in situ hybridization were performed on tissue samples
of cats with lymphoma [75]. In that study, FcaGHV1 was detected in some FIV-associated lymphomas,
and a positive FcaGHV1 intranuclear signal was visible by in situ hybridization in >90% of the cells in
a case of feline large granular lymphocyte lymphoma. These results demonstrated that FcaGHV1 was
present in feline lymphoma but only at low copy numbers, impairing the possibility of evaluating the
role of the virus in lymphomagenesis [75]. High FcaGHV1 tissue loads (48 FcaGHV1 genomes per cell)
were previously detected in a lymph node from a cat with high-grade T-cell intestinal lymphoma [76],
suggesting a certain variability of the viral loads within feline lymphoma subtypes. Further studies
investigating the cellular location and expression of FcaGHV1 antigens within neoplasias are needed
to clarify this possibility. In the present study, all tissue samples from cats with lymphoma—six clinical
cases testing negative for FeLV and FIV and 11 cats experimentally infected with FeLV and/or FIV—were
FcaGHV1-negative. One of the cats also had large granular lymphocyte lymphoma. It is important to
mention that the lack of association between FcaGHV1 and the development of lymphoma seen in the
present study does not rule out a role of FcaGHV1 in lymphomagenesis, especially considering the
inclusion of the tissue samples from the 11 SPF-cats that had been kept in a research facility under
barrier conditions. However, when the cats had been purchased from an accredited SPF breeding
facility some years ago, FcaGHV1 had not yet been discovered and no screening assays were available
to detect the virus. Thus, FcaGHV1 was not on the list of specified pathogens yet, and the cats had not
been tested for FcaGHV1 prior to the FeLV and/or FIV infection or throughout their lifespan. Thus, we
were pleased to recognize that the cats were free of FcaGHV1, and therefore FcaGHV1 was not the
underlying reason for the rather high frequency of lymphoma observed in our FeLV-infected SPF cats.
However, we recognize that the samples from the SPF cats may not be representative to assess the
contribution of FcaGHV1 to the development of lymphoma in field cats.
5. Conclusions
In conclusion, this large-scale epidemiological study including cats from all Swiss cantons showed
a molecular prevalence of 6.0%. Risk factors associated with FcaGHV1 detection were consistent
with those identified in previous studies and included nonpedigree status and male sex. Adult cats
(>3 years) were also at increased risk. Co-infection with other pathogens, such as hemoplasmas, FIV
and presumptively progressive FeLV infection, was also a risk factor for FcaGHV1 detection. Although
the molecular prevalence of FcGHV1 ranged from 0% to 16.7% in the different cantons, no clear influence
of geographic or climatic factors or the assumed cat density was found. The clinical importance of
FcaGHV1 is unclear, but the clinical information available only for a limited number of cats in the
present study revealed FcaGHV1-positive cats with leukemia, carcinoma and cardiomyopathy and
indicated that all 17 cats with lymphoma were FcaGHV1-negative. Further studies will be necessary to
elucidate the pathogenic potential of FcaGHV1 infections in domestic cats.
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